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Introduction 
The distinction between type 1 and type 
2 diabetes mellitus should be straight 
forward, based on age, body habitus, and 
type of presentation.  A specific diagnosis is 
important since treatments, associated 
abnormalities, and outcomes differ. 
Unfortunately, the distinction is not always 
that simple. We present a case of a patient 
with features of both types. 
 
Case Report 
A 57-year-old obese female patient 
presented with polyglandular failure 
manifested by early ovarian failure, growth 
hormone deficiency, autoimmune diabetes 
since age 18, and alopecia totalis.  Her Body 
Mass Index was 45.  She manifested features 
of  type 1 and type 2 diabetes. 
 
Table 1.  Features of diabetes observed in 
the patient. 
Type 1 features Type 2 features 
Positive Anti- 
Glutamic Acid 
Decarboxylase 
(GAD) 65 antibodies 
Persistent C-
peptide for 38 
years 
Diabetic ketoacidosis 
(several times) 
Hypertension 
Polyglandular 
autoimmune disease 
Dyslipidemia 
Intolerance to oral 
hypoglycemic 
Obesity 
 
 
Discussion 
Characteristics of the two diabetes 
entities can overlap as demonstrated by our 
patient.  Age is not as helpful anymore, 
since 10 percent of elderly diabetic patients 
have evidence of an autoimmune process1; 
conversely the incidence of type 2 diabetes 
accounts for 30% of new adolescent 
diagnoses.2 Presentation can be misleading. 
Diabetic ketoacidosis, the hallmark of type 1 
diabetes, also can be the presenting 
symptom in patients with type 2 diabetes.3 
Obesity is present in over 90% of 
adolescents and the majority of adults with 
type 2 diabetes, whereas only 25% of 
patients with type 1 diabetes are 
overweight.4 Approximately 30% of patients 
with type 2 diabetes have hypertension at 
presentation,5 but it is rare at presentation in 
patients with type 1 diabetes. 
C-peptide concentrations are usually 
high in patients with type 2 diabetes; 
hyperglycemia can cause transient insulin 
deficiency ("glucose toxicity") and a low 
initial plasma insulin level.  In patients with 
type 1 diabetes, the decline in insulin level is 
steady over time.6 Our patient maintained 
unexplainable normal to high C-peptide 
levels 38 years after diagnosis of type 1 
diabetes. No sufficient data were found in 
the literature that explained the persistence 
of insulin secretion for such a long period. 
Antibodies are present in 75 to 90% of 
patients with type 1 diabetes at present-
ation.7 Adults who are thought to have type 
2 diabetes and who have positive antibody 
tests eventually become insulin-dependent 
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and are considered to have latent 
autoimmune diabetes.8 
In the absence of reliable diagnostic 
markers greater emphasis must be placed on 
the findings in the individual patient. This 
case demonstrated some type 2 features in a 
patient with type 1 diabetes.  In daily 
practice, diagnoses often are generalized.  
Accurate diagnosis is important because the 
treatment and complications of type 1 and 
type 2 diabetes are distinct. Unfortunately, 
some cases of diabetes clearly cannot fit 
under a specific diagnosis.  
The ultimate goal of treatment for type 2 
diabetes is correction of the underlying 
insulin resistance through weight reduction, 
exercise, and medications.  Patients with 
type 1 disease are at risk for other 
autoimmune disorders, such as thyroid, 
celiac, and Addison's disease. Whereas, 
patients with type 2 disease are at risk for 
hypertension, dyslipidemias, and macro-
vascular disease. The genetic implications 
for other family members also differ for the 
two disorders.  
 
Conclusion 
Proper diagnosis of type 1 and type 2 
diabetes mellitus is crucial to the treatment 
that an affected patient is likely to receive.  
Type 1 and type 2 diabetes are two different 
entities although they may overlap. Some 
patients manifest features of both types at 
the same time. In the absence of specific 
markers between the two types, further 
evaluation with C-peptide levels and auto 
immune markers are appropriate to evaluate 
many adults with diabetes mellitus. 
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